Published: Dec 17, 2020 By Alex Keown
In August, Russia
approved Sputnik-V, a vaccine against COVID-19 ahead of the completion of Phase III studies. This week, the National Research Center for Epidemiology and Microbiology in that nation announced the vaccine’s efficacy is at 90% following the latest review of clinical data.
The efficacy announcement followed an analysis of Phase III data. Calculation was based on the analysis of data of volunteers who received both the first and second doses of the Sputnik V vaccine or placebo at the third and final control point of 78 confirmed cases in accordance with the Phase III clinical trials protocol, the government said. The advance to the third and final statistically significant representative control point allowed for the final proof of the efficacy of the vaccine of over 90%, the government said. Among the confirmed cases of coronavirus infection, 20 severe cases were recorded in the placebo group, while no severe cases